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Abstract 
BACKGROUND: Erdheim Chester disease (ECD) is a rare form of non-Langerhans histiocytosis that still 
presents a diagnostic and clinical dilemma.  
CASE PRESENTATION: We present a rare case of ECD, young 31 male with atypical localisation and soft tissue 
presentation and no bone involvement. He started clinical investigations due to subcutaneous tumour mass in the 
lumbar spine that caused severe back pain. Skin biopsy revealed ECD with Immunohistochemistry CD68+, 
CD10+, CD11c+, vimentin+, S100A4+. Activating BRAFV600E mutation was positive from the tumour tissue. The 
patient was referred to the haematology department. PET CT was performed for initial disease staging. Treatment 
was started with corticosteroids (methylprednisolone 0.5 mg/kg per day), and after 7 days, a significant clinical 
improvement was noticed in terms of pain disappearance with no need for pain killers. After two weeks, treatment 
with interferon Alfa (IFN-α) was started in a dose of 3 million units 3 times per week. After 4 months of interim 
treatment PET, CT revealed a significant reduction of the tumour mass. Therapy with IFN-α was continued, and 
the patient is still clinically in good condition.  
CONCLUSION: It can be concluded that shortening the time of diagnosis of ECD is essential in treatment 
outcome of this disease. Still, large studies have to confirm the best treatment of this rare condition. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Erdheim Chester disease (ECD) is a rare form 
of Non – Langerhans histiocytosis with unclear 
pathogenesis and aetiology and has been considered 
to be a non-neoplastic inﬂammatory disorder as well as 
a clonal neoplastic disorder [1]. The recent discovery 
of BRAFV600E mutations in ECD described the 
oncogenic nature of the disease, as well ECD 
histiocytes have been found to express a pattern of 
proinﬂammatory cytokines and chemokines 
responsible for local activation and recruitment of 
histiocytes [2]. The revised 2008 WHO classification 
of malignant haematological tumours proposed to 
assign separate histiocytic proliferations and ECD is 
one of the three new entities that is supposed to origin 
from interstitial dendritic cells. The idea to create 
these provisional entities was to enable to collect new 
cases for further studies and to maintain the purity of 
well-defined categories. One disease site may 
dominate the clinical presentation and require focused 
treatment in addition to the treatment of underlying 
ECD. Clinically, some patients have indolent and 
asymptomatic disease. Symptomatic ECD can be 
further categorised as multi-organ affection (CNS 
cardiovascular, pulmonary, soft tissue, retroperitoneal, 
etc.). Severe involvement of essentially any organ 
Case Report 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
2                                                                                                                                                                                                   https://www.id-press.eu/mjms/index 
 
system constitutes “high-risk” disease; therefore, the 
clinical phenotype of each patient is best 
characterised by the most pathophysiologically 
affected organ. ECD is a rare, multi-system disorder 
requiring multidisciplinary collaboration in its diagnosis 
and treatment. Guidelines for diagnosis and treatment 
of this disease are still to be refined in terms of 
generating trials with targeted molecular and 
immunologically based treatments which are essential 
to furthering therapeutic progress in ECD [3]. 
 
 
Case Presentation 
 
A newly diagnosed case of ECD is presented 
in this article, a 31 years adult male patient with 
multiple nodular subcutaneous tumours and aches in 
his back. He has been admitted to the plastic surgery 
clinic for diagnostic surgical biopsy (Figure 1 and 3). 
 
Figure 1: Nodular subcutaneous tumours in the lower back of the 
spinal cord 
 
Histopathology revealed chronic lymphocytic 
vasculitis, and he was referred to a rheumatologist for 
further immunological investigations and diagnostic 
evaluation. Due to intensive pain in the lumbar spinal 
cord, he performed MRI of the spinal cord, and a 
tumour mass in the subcutaneous tissue was noticed 
all over the spinal cord and in the retroperitoneal soft 
tissue region (Figure 2). 
 
Figure 2: MRI of the lumbar spine; On MRI a tumour mass was 
found in the subcutaneous tissue all over the back of the patient 
and in the retroperitoneal soft tissue region 
 
Figure 3: First skin biopsy No. 1130357: Oval skin excision 
measuring 1.9 x 0.8 cm with SFT measuring 1.1 cm has been 
received for histological analysis. Standard histological techniques 
have been used with H&E staining and immunohistochemical 
analysis for CD4, CD8, CD20, CD25, CD68, MCT 
 
He was suggested to perform second skin 
biopsy that still didn’t clear the diagnosis and was in 
favour of inflammatory vasculitis (Figure 4).  
 
Figure 4: Second skin biopsy: Oval skin excision measuring 
2.2x0.3cm with SFT measuring 1.1cm without peculiar features 
have been received for DIF analysis. IgG (-), IgM (-), IgA (-), C3c (-), 
C1q (-), Fibrin (-). Standard histological techniques have been used 
with H&E staining and PAS has been done 
 
The patient clinically worsens with severe 
pain in the lower lumbar spine. He was treated with 
NSAIL and analgesics. Due to persistent pain and 
negative results from immunological tests he performed 
third needle biopsy in which lymphocytes, plasma cells, 
and a large number of histiocytic cells with 
pleomorphic features; some of them with foamy 
cytoplasm, or eosinophilic cytoplasm and multinuclear 
giant cells. Pseudocysts lined with cells with histiocytic 
features were found. Immunohistochemistry revealed 
CD68+, CD10+, CD11c+, vimentin +, S100A4 +, 
negative for CD21, CD23, MAC387, S-100. The 
histopathology was in favour of ECD (Figure 5). 
 
Figure 5: Third core needle biopsy No.1133255: hypocellular 
collagenous tissue with entrapped accumulations from 
polymorphous cells: lymphocytes, plasma cells, and a large number 
of histiocytic cells with pleomorphic features; some of them with 
foamy cytoplasm, or eosinophilic cytoplasm and multinuclear giant 
cells. Pseudocysts lined with cells with histiocytic features were 
found. The histology confirmed ECD (CD68+, CD10+, CD11c+, 
S100A4+, vimentin+) 
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One patient was evaluated with 
histopathology findings from three skin biopsies 
performed in the Institute of Pathology, Medical 
Faculty, University “Ss. Cyril and Methodius”, Skopje, 
Republic of Macedonia. With the diagnostic 
confirmation of ECD, he was referred to University 
Clinic for haematology. Oncogenic nature of ECD with 
BRAF mutation was performed with RT-PCR. Imaging 
was performed with MRI and PET-CT. 
The patient was advised to continue 
evaluations and treatment at the haematology 
department. From haematological investigations 
activating BRAFV600E mutation was positive from the 
tumour tissue (RT PCR). Bone marrow biopsy was 
negative, with no infiltration for ECD. Laboratory blood 
tests were in the normal range. The patient performed 
initial PET CT for disease staging. PET CT revealed 
high metabolic activity in the gluteal region with deep 
subcutaneous infiltration and muscle affection (SUV 
6.0). 
Due to persistent lower back pain patient 
started treatment with corticosteroids 
(methylprednisolone) in a dose of 1mg/kg for one 
month. After one week he improved clinically with 
reduced pain, could perform the normal activity and 
he discontinued NSAIL and other analgesics. After 
diagnosis confirmation, his treatment followed with 
IFN alpha 3 million units 3 times per week for the next 
three months. After 3 months, a controlled PET CT 
was performed and revealed a significant reduction of 
tumour mass (SUV from 6 to 2.3). Therapy with IFN 
alpha was continued, and the patient is still clinically in 
good condition (Figure 6). 
 
Figure 6: PET CT in a patient with ECD initially revealed high 
metabolic activity in the gluteal region with deep subcutaneous 
infiltration and muscle affection (SUV max 6.0) (a) and 4 months 
after treatment initiation with a significant reduction of the tumour 
mass and infiltration (SUV max 2.3) (b) 
Discussion 
 
ECD is a rare form of non-Langerhans' cell 
histiocytosis, a disease with unclear pathophysiology, 
diagnostic dilemmas and still unknown treatment 
options. Individuals affected by this disease are 
typically adults between their 50 to 70 years, but 
patients between the ages of 7 to 84 years have been 
diagnosed [3]. Males and females are almost equally 
affected. The multisystemic form of ECD is associated 
with significant morbidity, which may arise due to 
histiocytic infiltration of critical organ systems. Among 
the more common sites of involvement are the 
skeleton, CNS, CVS, lungs, kidneys (retroperitoneum) 
and skin [4], [5]. The presented patient was 31 years 
of age male with no previous comorbidity and rare 
localisation of histiocytic infiltration, which caused 
diagnostic difficulties. The heterogeneous 
manifestations of ECD vary amongst different 
individuals. This results in a presentation that may 
vary from an indolent focal disease to life-threatening 
organ failure. The most common presenting symptom 
of ECD is bone pain. General symptoms are also 
described in most of the ECD cases like fever, fatigue, 
weight loss, loss of appetite and microcytic anaemia. 
The presented case was a rare soft tissue 
presentation of ECD with no bone lesions, which 
caused the diagnostic dilemma and became an ECD 
case with significance. The aetiology of ECD is 
unknown yet thought to be associated with an intense 
TH1 immune response. It may also be associated with 
the V600E BRAF mutation, as described in half of the 
patients in recent studies. Estimates of BRAFV600E 
mutation frequencies in ECD currently range between 
38% and 68% in most reports, with one recent report 
suggesting that nearly 100% (18/18) of ECD patients 
have the mutation, which opened a new treatment 
perspective for novel targeted therapy [6]. 
The diagnostic criteria of ECD are based on 
radiographic and histologic findings. Two biopsies that 
were initiated in the presented case revealed features 
of inflammatory vasculitis that did not correlate with 
the clinical manifestations, laboratory tests and 
molecular analysis. This was the reason to advise the 
patient for the third needle biopsy that confirmed ECD. 
Skeletal imaging is a very important diagnostic tool 
because in most of the ECD cases osteosclerotic 
bilateral changes in large bones can be found. Also, 
gamma scan assessment in ECD reveals abnormal 
strong labelling of distal bone ends of the large bones. 
The presented case has performed bone scintigraphy 
that revealed no tracer accumulation in distal parts of 
the large bones. CT scans of the lumbar region on two 
occasions didn’t reveal the existence of soft tissue 
lesion. After an MRI of the spine and PET CT, the 
lesion was detected. However, a definite diagnosis of 
ECD is established only once CD68 (+), CD1a (−) 
histiocytes are identified within a biopsy specimen. (7) 
There is no therapeutical consensus on ECD, 
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but it is evident that initiation of therapy should be soon 
after diagnosis confirmation, there is no evidence for 
observational studies. It is still of limited alternatives. 
Currently, interferon-α is the most extensively studied 
agent in the treatment of ECD and serves as the first 
line of treatment [8]. The IFN-α optimal dose is 3MU/3 
times per week in 3 years. There was no difference 
between IFN-α and pegylated formulations of IFN 
(Peg IFN-α). Dramatic efficacy was described in 3 
cases of ECD treated with Vemurafenib, but 
enrollment in a prospective clinical trial is essential to 
document efficacy and potential toxicities as well as to 
determine the duration of therapy. Treatment with 
other agents anticytokine agents, cladribine (2CDA), 
tocilizumab, sirolimus, imatinib, infliximab and 
anakinra are currently advocated as promising 
second-line treatments for patients whose response to 
interferon-α is unsatisfactory [9], [10]. Overall, the 5 
years survival of ECD is 68%. Disease surveillance is 
with organ-specific lesion imaging every 3 months 
after treatment initiation. After disease stabilisation, 
the intervals of the surveillance should be prolonged 
to 6 months. The presented case had PET CT 
imaging initially and 4 months after starting treatment 
with significant disease regression. There is no other 
cytokine marker that can be beneficial in disease 
surveillance period. C-reactive protein is usually 
elevated at the beginning of ECD and later decreased 
so that it can be used as a helpful biomarker in 
monitoring treatment. This case highlights the different 
clinical, radiological and pathological manifestations 
associated with ECD, the differential diagnoses and 
the various treatment options [11]. Due to a better 
characterisation of this entity, further studies that 
would shed new insights on the epigenetic and 
cytogenetic characteristics of ECD are needed, and 
further correlation with morphological and 
immunophenotypic features is also needed. 
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